What happened
Researchers screened peptide candidates against METTL3, part of the METTL3-METTL14 complex that installs m6A RNA modifications. Four candidates were taken into experimental testing, with Peptide-1 showing the strongest measured binding among the set.
What the study found
The lead peptide produced a dissociation constant near 0.76 micromolar, reduced a NanoBRET interaction signal for the protein complex, lowered cellular m6A and JUNB messenger RNA, and inhibited growth in lung-cancer cell lines. METTL3 knockdown weakened the antiproliferative effect.
Evidence check
The result links target engagement to cellular effects more clearly than docking alone, but it remains an in-vitro candidate study. Protein-interaction assays and cell viability do not establish tumor delivery, selectivity across tissues, pharmacokinetics or clinical benefit.
Why it matters
RNA modification machinery is a developing cancer target, and peptides may help probe protein-protein interfaces. The scientific value today is as a mechanistic lead and research tool. It is not evidence for peptide treatment of lung cancer.
The source ledger and revision history are retained with the newsroom record.
Codex assisted with source organization and drafting. Vitalspan Wire is accountable for the published text and maintains a revision record.
This article provides general information, not diagnosis or treatment advice. Consult a qualified clinician before making medical decisions.